var data={"title":"Calfactant: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calfactant: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5797?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calfactant-drug-information\" class=\"drug drug_general\">see &quot;Calfactant: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144833\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Infasurf</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057146\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Lung Surfactant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442190\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory distress syndrome (RDS): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylactic</i>\n      <i> therapy:</i> Premature newborns (&lt;29 weeks' gestation): Endotracheal: 3 mL/kg as soon as possible after birth, preferably within 30 minutes; additional doses may be given every 12 hours up to a total of 3 doses. In studies, repeat doses have been administered as frequently as every 6 hours for a total of up to 4 doses if the neonate was still intubated and required at least 30% inspired oxygen to maintain arterial oxygen saturations &gt;90% or with a PaO<sub>2</sub> &le;80 torr on &gt;30% inspired oxygen (Bloom 2005; Kattwinkel 2000). However, guidelines suggest that dosing intervals more frequent than every 12 hours should not be necessary, unless surfactant is being inactivated by an infectious process, meconium, or blood (AAP [Polin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Rescue treatment:</i> Newborns &le;72 hours: Endotracheal: 3 mL/kg as soon as the diagnosis of RDS is made; additional doses may be given every 12 hours up to a total of 3 doses. In studies, repeat doses have been administered as frequently as every 6 hours for a total of up to 4 doses if the neonate was still intubated and required at least 30% inspired oxygen to maintain arterial oxygen saturations &gt;90% or with a PaO<sub>2</sub> &le;80 torr on &gt;30% inspired oxygen (Bloom 2005; Kattwinkel 2000). However, guidelines suggest that dosing intervals more frequent than every 12 hours should not be necessary, unless surfactant is being inactivated by an infectious process, meconium, or blood (AAP [Polin 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50934011\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=calfactant-drug-information\" class=\"drug drug_general\">see &quot;Calfactant: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144823\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intratracheal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infasurf: 35 mg phospholipids and 0.7 mg protein per mL (3 mL, 6 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144811\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057149\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Endotracheal tube administration: Gently swirl to redisperse suspension; do not shake; administer dosage divided into two aliquots of 1.5 mL/kg each into the endotracheal tube; after each instillation, reposition the infant with either the right or left side dependent; administration is made while ventilation is continued over 20 to 30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles; a pause followed by evaluation of the respiratory status and repositioning should separate the two aliquots; calfactant dosage has also been divided into four equal aliquots and administered with repositioning in four different positions (prone, supine, right and left lateral) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144831\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Gentle swirling or agitation of the vial of suspension is often necessary for redispersion. <b>Do not shake</b>. Visible flecks of the suspension and foaming under the surface are normal. Calfactant should be stored upright (3 mL vial) and under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light; document date and time removed from refrigeration. Warming before administration is not necessary. Unopened and unused vials of calfactant that have been warmed to room temperature can be returned to refrigeration storage within 24 hours for future use. Repeated warming to room temperature should be avoided. Each single-use vial should be entered only once and the vial with any unused material should be discarded after the initial entry.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057148\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention of respiratory distress syndrome (RDS) in premature infants at significant risk (FDA approved in newborns &lt;29 weeks gestational age); treatment of RDS in neonates with clinical and radiologic confirmation and requiring mechanical ventilation (FDA approved in newborns &le;72 hours of age) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144844\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Bradycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Endotracheal tube reflux</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Airway obstruction, cyanosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25595601\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;\"> There are no contraindications listed in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144815\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transient adverse effects: Transient episodes of bradycardia, decreased oxygen saturation, endotracheal tube blockage or reflux of calfactant into endotracheal tube may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: For intratracheal administration only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298945\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218819\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13109&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057145\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Continuous heart rate and transcutaneous O<sub>2</sub> saturation should be monitored during administration; frequent ABG sampling is necessary to prevent postdosing hyperoxia and hypocarbia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144814\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous lung surfactant is essential for effective ventilation because it modifies alveolar surface tension, thereby stabilizing the alveoli. Lung surfactant deficiency is the cause of respiratory distress syndrome (RDS) in premature infants and lung surfactant restores surface activity to the lungs of these infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F144827\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">No human studies of absorption, biotransformation, or excretion have been performed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46305898\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Calfactant contains surfactant-associated proteins SP-B and SP-C (0.7 mg/mL protein, including 0.26 mg/mL SP-B).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323037\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Infasurf Intratracheal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg/mL 0.9% (3 mL): $455.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24672835\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Infasurf (IL, JO, KR, KW, QA, SA, SG, UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bloom BT, Clark RH, and Infasurf Survanta Clinical Trial Group, &quot;Comparison of Infasurf (Calfactant) and Survanta (Beractant) in the Prevention and Treatment of Respiratory Distress Syndrome,&quot; <i>Pediatrics</i>, 2005, 116(2):392-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calfactant-pediatric-drug-information/abstract-text/16061594/pubmed\" target=\"_blank\" id=\"16061594\">16061594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infasurf (calfactant) [prescribing information]. Amherst, NY: ONY, Inc; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kattwinkel J, Bloom BT, Delmore P, et al, &quot;High- Versus Low-Threshold Surfactant Retreatment for Neonatal Respiratory Distress Syndrome,&quot; <i>Pediatrics</i>, 2000, 106(2 Pt 1):282-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calfactant-pediatric-drug-information/abstract-text/10920152/pubmed\" target=\"_blank\" id=\"10920152\">10920152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polin RA, Carlo WA, Committee on Fetus and Newborn, American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. <i>Pediatrics</i>. 2014;133(1):156-163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calfactant-pediatric-drug-information/abstract-text/24379227 /pubmed\" target=\"_blank\" id=\"24379227 \">24379227 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13109 Version 77.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F144833\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057146\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442190\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F50934011\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F144823\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F144811\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057149\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F144831\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057148\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F144844\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25595601\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F144815\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298945\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218819\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057145\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F144814\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F144827\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F46305898\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323037\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24672835\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13109|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calfactant-drug-information\" class=\"drug drug_general\">Calfactant: Drug information</a></li></ul></div></div>","javascript":null}